免费获得国外相关药品，最快 1 个工作日回馈药物信息
CD160 Expression in Retinal Vessels is Associated With Retinal Neovascular Diseases (NEOVASC-CD160)
The aims of this study were
- to analyze CD160 expression in both normal and pathological eyes from human adults
- to evaluate association between CD160 presence on endothelial cells from blood vessels and retinal vascular disease
| Condition or disease | Intervention/treatment |
|---|---|
| Surgical Retinal | Other: immunohistochemistry on Formalin fixed and paraffin embedded blocks |
Anti-angiogenic agents stand first in the treatment of neovascular diseases of the retina. Intravitreal injections of anti-Vascular Endothelial Growth Factor (VEGF) agents have emerged over the past decade as the first line of treatment in some neovascular diseases of the retina. Nevertheless, anti-VEGF therapies suffer some limitations, among which a short time to recurrence (1 week to 3 months) of retinal neovascularization and an eroding biological effect after prolonged use and.
CD160 appeared in several experimental studies as a marker of activated endothelial cells, suggesting it could represent a promising target for novel anti-angiogenic.
| Study Type : | Observational |
| Actual Enrollment : | 75 participants |
| Observational Model: | Case-Control |
| Time Perspective: | Retrospective |
| Official Title: | CD160 Expression in Retinal Vessels is Associated With Retinal Neovascular Diseases |
| Actual Study Start Date : | January 2008 |
| Actual Primary Completion Date : | January 2017 |
| Actual Study Completion Date : | July 2017 |
| Group/Cohort | Intervention/treatment |
|---|---|
|
neovascular group
patients with diabetic retinopathy, retinal vein occlusion complicated with iris rubeosis or neovascular glaucoma, ocular ischaemic syndrome, neovascular glaucoma secondary to any ocular event or iris rubeosis secondary to retinal detachment
|
Other: immunohistochemistry on Formalin fixed and paraffin embedded blocks |
|
non-neovascular group
patients without neovascular diseases or complications but who underwent events leading to eye surgery such as trauma, endophthalmitis, cellulitis, anterior perforation, corneal abscess or retinal detachment.
|
Other: immunohistochemistry on Formalin fixed and paraffin embedded blocks |
- CD160 staining intensity score [ Time Frame: Day0 ]
Formalin fixed and paraffin embedded blocks were used for immunohistochemistry using CD160.
The immunolabelling was evaluated independently by 2 observers (CBR, AH) blinded to clinical data. The staining intensity (0: absent, 1: faint, 2: moderate, 3: strong) was assessed for CD160 immunolabelling.
- CD105 staining intensity score [ Time Frame: Day0 ]
Formalin fixed and paraffin embedded blocks were used for immunohistochemistry using CD105.
The immunolabelling was evaluated independently by 2 observers (CBR, AH) blinded to clinical data. The staining intensity (0: absent, 1: faint, 2: moderate, 3: strong) was assessed for CD105 immunolabelling.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
inclusion criteria :
- Patients with retinal surgery
- Patients who agree to participate to the study
- Major patient
exclusion criteria :
- Patient under law protection
- Minor patient
| France | |
| Chu Reims | |
| France, Reims, France, 51092 | |
| Tracking Information | |||||
|---|---|---|---|---|---|
| First Submitted Date | May 6, 2019 | ||||
| First Posted Date | May 7, 2019 | ||||
| Last Update Posted Date | May 7, 2019 | ||||
| Actual Study Start Date | January 2008 | ||||
| Actual Primary Completion Date | January 2017 (Final data collection date for primary outcome measure) | ||||
| Current Primary Outcome Measures |
CD160 staining intensity score [ Time Frame: Day0 ] Formalin fixed and paraffin embedded blocks were used for immunohistochemistry using CD160.
The immunolabelling was evaluated independently by 2 observers (CBR, AH) blinded to clinical data. The staining intensity (0: absent, 1: faint, 2: moderate, 3: strong) was assessed for CD160 immunolabelling.
|
||||
| Original Primary Outcome Measures | Same as current | ||||
| Change History | No Changes Posted | ||||
| Current Secondary Outcome Measures |
CD105 staining intensity score [ Time Frame: Day0 ] Formalin fixed and paraffin embedded blocks were used for immunohistochemistry using CD105.
The immunolabelling was evaluated independently by 2 observers (CBR, AH) blinded to clinical data. The staining intensity (0: absent, 1: faint, 2: moderate, 3: strong) was assessed for CD105 immunolabelling.
|
||||
| Original Secondary Outcome Measures | Same as current | ||||
| Current Other Pre-specified Outcome Measures | Not Provided | ||||
| Original Other Pre-specified Outcome Measures | Not Provided | ||||
| Descriptive Information | |||||
| Brief Title | CD160 Expression in Retinal Vessels is Associated With Retinal Neovascular Diseases | ||||
| Official Title | CD160 Expression in Retinal Vessels is Associated With Retinal Neovascular Diseases | ||||
| Brief Summary |
The aims of this study were
|
||||
| Detailed Description |
Anti-angiogenic agents stand first in the treatment of neovascular diseases of the retina. Intravitreal injections of anti-Vascular Endothelial Growth Factor (VEGF) agents have emerged over the past decade as the first line of treatment in some neovascular diseases of the retina. Nevertheless, anti-VEGF therapies suffer some limitations, among which a short time to recurrence (1 week to 3 months) of retinal neovascularization and an eroding biological effect after prolonged use and. CD160 appeared in several experimental studies as a marker of activated endothelial cells, suggesting it could represent a promising target for novel anti-angiogenic. |
||||
| Study Type | Observational | ||||
| Study Design | Observational Model: Case-Control Time Perspective: Retrospective |
||||
| Target Follow-Up Duration | Not Provided | ||||
| Biospecimen | Not Provided | ||||
| Sampling Method | Non-Probability Sample | ||||
| Study Population | Patients with surgical retinal | ||||
| Condition | Surgical Retinal | ||||
| Intervention | Other: immunohistochemistry on Formalin fixed and paraffin embedded blocks | ||||
| Study Groups/Cohorts |
|
||||
| Publications * | Henry A, Boulagnon-Rombi C, Menguy T, Giustiniani J, Garbar C, Mascaux C, Labrousse M, Milas C, Barbe C, Bensussan A, Durlach V, Arndt C. CD160 Expression in Retinal Vessels Is Associated With Retinal Neovascular Diseases. Invest Ophthalmol Vis Sci. 2018 Jun 1;59(7):2679-2686. doi: 10.1167/iovs.18-24021. | ||||
|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
| Recruitment Information | |||||
| Recruitment Status | Completed | ||||
| Actual Enrollment |
75 | ||||
| Original Actual Enrollment | Same as current | ||||
| Actual Study Completion Date | July 2017 | ||||
| Actual Primary Completion Date | January 2017 (Final data collection date for primary outcome measure) | ||||
| Eligibility Criteria |
inclusion criteria :
exclusion criteria :
|
||||
| Sex/Gender |
|
||||
| Ages | 18 Years and older (Adult, Older Adult) | ||||
| Accepts Healthy Volunteers | No | ||||
| Contacts | Contact information is only displayed when the study is recruiting subjects | ||||
| Listed Location Countries | France | ||||
| Removed Location Countries | |||||
| Administrative Information | |||||
| NCT Number | NCT03940664 | ||||
| Other Study ID Numbers | 2018Ao001 | ||||
| Has Data Monitoring Committee | No | ||||
| U.S. FDA-regulated Product |
|
||||
| IPD Sharing Statement |
|
||||
| Responsible Party | CHU de Reims | ||||
| Study Sponsor | CHU de Reims | ||||
| Collaborators | Not Provided | ||||
| Investigators | Not Provided | ||||
| PRS Account | CHU de Reims | ||||
| Verification Date | May 2019 | ||||
